Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara’s pipeline includes tabelecleucel for EBV-driven post-transplant lymphoproliferative disease (PTLD) and other EBV-associated diseases, next-generation CAR T therapies for cancers, and ATA188 for Multiple Sclerosis.
Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company leveraging its novel EBV T-cell platform to develop therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.
Press Releases
Products